NEWARK, Del, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The brain tumor drugs market is likely to grow from US$ 2.65 billion in 2023 to US$ 6.30 billion in 2033. Prevalence of smoking, stress, aging, and electromagnetic radiation is projected to drive market growth. Increasing cases of brain cancer are expected to propel the market course. Presence of strong key players in the market is projected to assist in market development. FMI shares this information in its report titled “Brain Tumor Drugs Market, 2023 to 2033.
Growing Use of Targeted Medicines is Putting a Damper on the Brain Tumor Medications Industry
The purpose of targeted cancer therapy is to kill malignant cells while leaving healthy cells alone. This therapy may be more effective than traditional chemotherapy and radiotherapy because it focuses on changes in the cell that are particular to cancer. Everolimus, for example, is a targeted medication that prevents cancer cells from growing and spreading.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16725
Similarly, unlike chemical medications, which cannot block regeneration, Bevacizumab prevents cancer cell regeneration. The increased popularity of targeted therapy is likely to impact sales of conventional chemical brain tumor medications, limiting market growth over the projection period. Companies in the brain tumor market are concentrating on the application of nanotechnology for innovative treatment.
Nanoparticles are utilized to deliver medications in combination straight to cancer cells or into tumors. This method has also resulted in a reduction in medicine dosage, increased shelf life, and reduced toxicity. A few nano drugs are proven to be effective in crossing the blood-brain barrier, which has been a substantial obstacle in the treatment of brain malignancies.
A brain tumor is an abnormal mass of tissue in which brain cells grow and replicate in an uncontrollable and fast manner. Brain cancers are classified into two types: primary brain tumors and metastatic brain tumors. Primary brain tumors are those that arise from the brain's tissues or its surrounding tissues.
Pharmaceutical businesses have improved supply chain management, which has increased research and development and investment in quality control and manufacturing.
Key Takeaways
- The brain tumor drugs market is expected to record a CAGR of 9.2% during the forecast period 2023 to 2033.
- The primary drivers of the market are an increase in brain cancer prevalence, the presence of promising pipeline candidates, and an increased need for precision and customized treatment to drive market expansion.
- North America dominated the brain tumor drugs market.
View Complete Report@ https://www.futuremarketinsights.com/reports/brain-tumor-drugs-market
Key Development in the Brain Tumor Drugs Market
- April 2021 - MindMed and Nextage Therapeutics signed a Memorandum of Understanding (MOU) to maximize the administration of selected psychedelic drug candidates using Nextage's unique Brain Targeting Liposome System (BTLS) delivery technology.
- March 2021 - Roche and GenMark Diagnostics signed a comprehensive merger agreement for Roche to entirely acquire GenMark for US$ 24.05 per share in an all-cash transaction.
- September 2022 - F. Hoffmann-La Roche Ltd. announced an agreement to acquire Good Therapeutics. With this acquisition, the firm gains access to Good Therapeutic's platform technology, which is relevant to a wide range of sectors such as cancer, autoimmune illnesses, metabolic disease, and pain management.
- June 2022 - Novartis AG received the United States FDA approval for Tafinlar + Mekinist for the treatment of paediatric and adult patients with solid cancers containing the BRAF V600E mutation. BRAF mutations are responsible for tumor growth in over 20 different tumor types, including brain, thyroid, and others.
- November 2021 - Pfizer Inc. purchased Trillium Therapeutics, a clinical-stage immuno-oncology startup focused on creating novel cancer medicines.
Key Players:
- AstraZeneca plc
- Johnson & Johnson Inc
- Merck & Co
- Pfizer Inc
- F. Hoffmann-La Roche Ltd
- Y-mAbs Therapeutics, Inc
- Shimadzu Corporation
- Bristol-Myers Squibb
- Bayer AG
- Dr. Reddy's Laboratories Ltd
- Among others
Key Segment
By Therapy:
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Others
By Indication:
- Pituitary
- Meningioma
- Glioma
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail & Online Pharmacy
Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16725
Table of Content
1. Executive Summary | Brain Tumor Drugs Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
Buy Now@ https://www.futuremarketinsights.com/checkout/16725
About the Healthcare at Future Market Insights
The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 Billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at Related Reports of Healthcare domain
Adiponectin Testing Market Size: The adiponectin testing market is projected to expand its roots in the global market at a CAGR of 7.9% during the forecast period 2022-2032.
Mobile Computed Tomography Scanners Market Share: The mobile computed tomography scanners market is likely to record a CAGR of 5.5% during the forecast period of 2022 to 2032.
Multiplex Molecular Diagnostics Market Demand: The multiplex molecular diagnostics market has anticipated a CAGR of 5.4% during the forecast period, up from US$ 23.2 Billion in 2022 to reach the valuation of US$ 39.25 Billion by 2032.
Dyslexia Treatments Market Growth: The global dyslexia treatment market is anticipated to touch a market worth US$ 8061.5 Million in 2032, increasing from US$ 4096.1 Million in 2022 and growing at a CAGR of 6.3% during the forecast period.
Disposable Insulin-Delivery Device Market Overview: The global disposable insulin-delivery device market is anticipated to be valued at US$ 14,585.6 Million in 2022, forecast to grow at a CAGR of 7.7% to be valued at US$ 32,887.5 Million from 2022 to 2032.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, US, and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
